Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 04, 2015 8:43 AM ET

Diversified Consumer Services

Company Overview of The University of Texas M. D. Anderson Cancer Center

Company Overview

The University of Texas M. D. Anderson Cancer Center is an educational institution that offers undergraduate and research programs to physicians, biomedical scientists, and other health-care professionals. The departments include behavioral medicine, biochemistry and molecular biology, cancer biology program, cancer genomics core laboratory, molecular and cellular oncology, molecular genetics, molecular hematology and therapy, molecular therapeutics, and molecular pathology. The University of Texas M. D. Anderson Cancer Center was founded in 1941 as Texas State Cancer Hospital and the Division of Cancer Research and changed its name to M. D. Anderson Hospital for Cancer Research of The Unive...

1515 Holcombe Boulevard

Houston, TX 77030

United States

Founded in 1989



Key Executives for The University of Texas M. D. Anderson Cancer Center

Age: 59
Executive Vice President and Physician-In-Chief
Chairman of Department of Health Disparities Research
Vice President and Head of the Division of Pharmacy
Compensation as of Fiscal Year 2014.

The University of Texas M. D. Anderson Cancer Center Key Developments

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center Announces Signing of Option Agreement to Research and Develop New Treatment for Patients with Acute Myeloid Leukemia

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center announced signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML). The collaboration grants Astellas an option to firstly negotiate an exclusive, worldwide license at the end of Phase Ib, with both Phase Ia and Phase Ib studies to be conducted by MD Anderson. The agreement also includes up to $26 million as an option premium and research and development funding. The collaboration will focus on h8F4 technology, a humanized monoclonal antibody invented by Jeffrey Molldrem, M.D., professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson. The antibody h8F4 targets an HLA-restricted peptide called PR1/HLA-A2, which is expressed in cancer cells and cancer stem cells. Molldrem will lead these research efforts with Carlo Toniatti, M.D., Ph.D., executive director of MD Anderson's Oncology Research for Biologics and Immunotherapy Translation (ORBIT) platform. While monoclonal antibodies are very common in oncology, generating antibodies against HLA-restricted peptides has proven difficult. To develop viable antibody drugs, MD Anderson created ORBIT for its Moon Shots Program to centralize this type of research. The program is an ambitious initiative to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths.

NanoString Technologies and University of Texas MD Anderson Cancer Center to Collaborate on Development of Multi-Omic Assays Simultaneously Profiling Gene and Protein Expression

The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc. announced a multi-year collaboration to accelerate the development and adoption of a revolutionary new type of assay based on NanoString's nCounter Analysis System. The collaboration will involve the development of "multi-omic" assays, which simultaneously profile both gene and protein expression, with a primary focus on identifying important biomarkers in the burgeoning field of immuno-oncology as well as extending programs for targeting therapeutics. Key objectives of the collaboration include: development of new multi-omic assays and signatures that profile key oncology disease pathways and immune response from tumor tissue; incorporation of these multi-omic assays into select clinical studies being run at MD Anderson to predict response and monitor response to cancer immuno-therapies and targeted therapies, both as single agents and combinations; and identification of clinically actionable proteomic markers across multiple tumor types. Under the terms of the agreement, NanoString is granted rights to research and diagnostic content developed within the scope of the collaboration.

The University of Texas MD Anderson Cancer Center Appoints Patrick Hwu as Division Head of Cancer Medicine

The University of Texas MD Anderson Cancer Center has appointed Patrick Hwu as division head of cancer medicine. Champlin will continue to serve as chair of Stem Cell Transplantation and Cellular Therapy. He has also held endowed positions, including the Sheikh Mohamed Bin Zayed Al Nahyan Distinguished University Chair in Cancer Research. He joined MD Anderson in 2003 as the first chair of Melanoma Medical Oncology. .

Similar Private Companies By Industry

Company Name Region
Good Shepherd Auto Glass, Inc. United States
Whitehall Funeral Home United States
Clean Air Refrigerant Recovery & Reclamation, Inc. United States
City Auto Glass, Inc. United States
StoneMor South Carolina LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The University of Texas M. D. Anderson Cancer Center, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at